HempFusion Wellness Inc. (CBD.U)

[fil]

HempFusion Wellness Announces Toxicology Results from Validcare’s Clinical Study on CBD Liver Safety
Tue March 23, 2021 9:20 AM|Business Wire|About: CBDHF

DENVER, Colo.--(BUSINESS WIRE)-- HempFusion Wellness Inc. (CBDHF) (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce that Validcare, the organization coordinating the execution of what the Company believes to be the largest human observational, liver and human toxicology study to date, has released its initial findings from the industry sponsored, decentralized human safety study of hemp derived CBD products. The preliminary findings are validating and encouraging, and according to the study’s investigators, there was no evidence of liver toxicity in the 839 participants in the clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005376/en/